Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a report issued on Sunday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Price Performance

CHEK stock opened at $0.77 on Friday. The firm has a market capitalization of $4.51 million, a P/E ratio of -0.26 and a beta of 0.19. Check-Cap has a 52-week low of $0.56 and a 52-week high of $3.45. The company’s 50 day simple moving average is $1.05 and its 200-day simple moving average is $1.19.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.